EXOZ Invizyne Technologies: Enterprise Value-to-Revenue Multiple

invizyne.com (EXOZ) - corporate logo

The price-to-sales ratio provided by the GURU.Markets platform indicates the impact of strict EPA regulations and synthesis patent protection. The 0.00 level captures fresh values as eXoZymes Inc (EXOZ) implements AI control within automated laboratories. The development of sustainable fuel production via invizyne.com and the demand for green chemistry serve as key growth drivers for the eXoZymes Inc (EXOZ) business.

EXOZ - eXoZymes Company Value to Revenue over the range 11/23/2025 - 11/20/2026

invizyne.com - analytical breakdowns and key metrics (EXOZ)

- share price and consensus valuation forecast:
Initial company analysis:EXOZ (eXoZymes)
Manufactured product of eXoZymes Inc

The EV/Sales ratio compares the total enterprise value of a business, including debt, to the volume of revenue generated. This metric determines the market premium per unit of sales, excluding the influence of capital structure. For eXoZymes Inc (EXOZ), which relies on an elite staff of biologists and R&D intensity, this serves as an indicator of the capitalization of its intellectual potential. Analysis of the EV/Sales chart allows for an assessment of whether current investor expectations are justified. An increase in this ratio signals market confidence in the success of cell-free biomanufacturing.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio